MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
MindMed (NASDAQ: MNMD), a late-stage biopharmaceutical company focused on brain health disorders, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management team will engage in a fireside chat and one-on-one meetings during the virtual event, scheduled for February 12, 2025, at 9:20 AM ET.
Audio webcasts and replays of the presentations will be made available on MindMed's Investor Relations website, remaining accessible for up to 90 days after the event. This conference participation represents an opportunity for the company to showcase its developments in brain health treatments to the investment community.
MindMed (NASDAQ: MNMD), un'azienda biopharmaceutical di fase avanzata focalizzata sui disturbi della salute mentale, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Salute di Oppenheimer. Il team di gestione dell'azienda parteciperà a una chiacchierata informale e a incontri individuali durante l'evento virtuale, programmato per il 12 febbraio 2025, alle 9:20 AM ET.
I webcast audio e le riproduzioni delle presentazioni saranno disponibili sul sito web delle Relazioni con gli Investitori di MindMed, rimanendo accessibili fino a 90 giorni dopo l'evento. Questa partecipazione alla conferenza rappresenta un'opportunità per l'azienda di mostrare i propri progressi nei trattamenti per la salute mentale alla comunità degli investitori.
MindMed (NASDAQ: MNMD), una empresa biofarmacéutica de última etapa enfocada en los trastornos de la salud cerebral, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. El equipo de gestión de la empresa participará en una charla informal y en reuniones uno a uno durante el evento virtual, programado para el 12 de febrero de 2025, a las 9:20 AM ET.
Los webcasts de audio y las repeticiones de las presentaciones estarán disponibles en el sitio web de Relaciones con Inversores de MindMed, accesibles por hasta 90 días después del evento. Esta participación en la conferencia representa una oportunidad para que la empresa muestre sus desarrollos en tratamientos de salud cerebral a la comunidad inversora.
MindMed (NASDAQ: MNMD), 뇌 건강 질환에 중점을 둔 후기 단계 생명공학 회사가 Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진 팀은 2025년 2월 12일 오전 9:20 ET에 예정된 가상 이벤트 동안 화상 대화와 일대일 회의에 참여할 것입니다.
오디오 웹캐스트와 프레젠테이션 재생은 MindMed의 투자자 관계 웹사이트에서 제공되며, 이벤트 후 최대 90일 동안 접근할 수 있습니다. 이 컨퍼런스 참여는 회사가 투자 커뮤니티에 뇌 건강 치료의 발전을 선보일 수 있는 기회를 의미합니다.
MindMed (NASDAQ: MNMD), une entreprise biopharmaceutique en phase avancée axée sur les troubles de la santé cérébrale, a annoncé sa participation à la 35ème Conférence Annuelle sur les Sciences de la Santé d'Oppenheimer. L'équipe de direction de l'entreprise participera à une discussion informelle et à des réunions individuelles pendant l'événement virtuel, prévu pour le 12 février 2025 à 9h20 ET.
Des webcasts audio et des rediffusions des présentations seront disponibles sur le site des Relations Investisseurs de MindMed, accessibles pendant jusqu'à 90 jours après l'événement. Cette participation à la conférence représente une opportunité pour l'entreprise de présenter ses avancées dans les traitements de la santé cérébrale à la communauté des investisseurs.
MindMed (NASDAQ: MNMD), ein Biopharma-Unternehmen in der späten Entwicklungsphase, das sich auf Störungen der Gehirngesundheit konzentriert, hat seine Teilnahme an der 35. jährlichen Gesundheits- und Lebenswissenschaftskonferenz von Oppenheimer angekündigt. Das Management-Team des Unternehmens wird an einem informellen Gespräch und persönlichen Meetings während der virtuellen Veranstaltung teilnehmen, die für den 12. Februar 2025 um 9:20 Uhr ET angesetzt ist.
Audio-Webcasts und Wiederholungen der Präsentationen werden auf der Investor-Relations-Website von MindMed verfügbar gemacht und sind bis zu 90 Tage nach der Veranstaltung zugänglich. Diese Teilnahme an der Konferenz stellt eine Gelegenheit für das Unternehmen dar, seine Entwicklungen in der Behandlung von Gehirngesundheit der Investoren-Community vorzustellen.
- None.
- None.
-
Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Format: Fireside Chat and 1x1 Meetings
- Date: February 12, 2025 at 9:20 AM ET
- Location: Virtual
- Webcast Link: Oppenheimer 35th Annual Healthcare Life Sciences Conference
Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.
About MindMed
MindMed is a late-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204403989/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
When is MindMed (MNMD) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access MindMed's (MNMD) Oppenheimer Conference presentation?
What type of presentation will MNMD deliver at the Oppenheimer Conference?
How long will MNMD's Oppenheimer Conference presentation be available for replay?
